Access Keys:
Skip to content (Access Key - 0)

Center for Cancer Research National Cancer Institute
NCI Drug Development Collaborative

The Proposal Process

If you have determined you have a good target and a good compound

The Proposal

Investigators need to prepare a concise, one page proposal for the DDC that illustrates all the points that determined you have identified a good target and a good compound in addition to any of the points which may strengthen the proposal. All relevant publications of your work which support the proposal should also be submitted. You may also address issues which you may need assistance.

The DDC meets every other month to discuss all submitted proposals. You will asked to give a short presentation to the DDC followed by a detailed discussion. After public and private discussions, the DDC will vote on the proposal. You will receive written notification from the DDC on their decision.

 

There are three different options:

1) Proposal not supported by DDC- Committee felt proposal failed to demonstrate agent as good target and/or good compound.

2) More work needed- Committee felt more experiments were needed to determine if agent was as good target and/or good compound. Investigators are encouraged to perform the additional experiments and then come back to the DDC to present findings. The committee will re-review proposal and vote again.

3) Approved/Submit to NExT- Committee felt agent merits approval and is ready to be submitted to the NExT. Proposal will go to either the NCI Early Drug Discovery Committee or the NCI Drug Development Committee.

Contact

Proposals should be submitted to Pat Steeg (steegp@mail.nih.gov).

 



[Previous page] | [Next Page]

Added by Boersma, Brenda (NIH/NCI) [E] , last edited by Boersma, Brenda (NIH/NCI) [E] on Mar 25, 2013 10:29